Clinical Trials

Below is a listing of clinical trials conducted at MUSC Hollings Cancer Center. Use the tools in the left toolbar to refine your search. If you are interested in Early Phase/Multi Tumor trials, select the program “Phase I Unit.” Please note that cohort information for the Phase I trials changes often.

Clinical Research Group Intranet
Hold Ctrl (Cmd on Mac) to select multiple.
Protocol Title Status Docs
104333 A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS) OPEN TO ACCRUAL

104270 Omission of Post-Operative Radiation in Patients with Intermediate Pathological Risk Features and Negative Two Week Post-Operative ctHPVDNA (OPERATION Trial) OPEN TO ACCRUAL

104177 A Phase III, Open-Label, Multi-Center, Randomized Study Comparing AAA817 Plus ARPI Versus Standard of Care in Adult Participants with PSMA-Positive Metastatic Castration Resistant Prostate Cancer OPEN TO ACCRUAL

104156 A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-nave Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL) OPEN TO ACCRUAL

104241 A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors OPEN TO ACCRUAL

104243 A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma OPEN TO ACCRUAL

104085 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy of Visugromab in Combination with Pembrolizumab, Pemetrexed, and Cis- /Carboplatin in Participants with Newly Diagnosed Metastatic Non-Squamous Non-Small Cell Lung Cancer OPEN TO ACCRUAL

104205 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis OPEN TO ACCRUAL

104292 CA266-0008: ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC) OPEN TO ACCRUAL

104185 A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer OPEN TO ACCRUAL

104289 A randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T-Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) OPEN TO ACCRUAL

103565 A Phase 1a "Window Trial" on Cannabidiol (CBD) for Breast Cancer Primary Tumors OPEN TO ACCRUAL

104196 Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy OPEN TO ACCRUAL

104161 A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer OPEN TO ACCRUAL

104271 A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade OPEN TO ACCRUAL

104201 WATER IV Prostate Cancer: Aquablation versus Radical Prostatectomy for the Treatment of Localized Prostate Cancer OPEN TO ACCRUAL

104178 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4) OPEN TO ACCRUAL

104267 NRG-GU015: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER) OPEN TO ACCRUAL

104263 A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) OPEN TO ACCRUAL

104122 Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) OPEN TO ACCRUAL